Aft Pharmaceuticals
AFT signs new deal but maintains profit guidance
Drug company AFT Pharmaceuticals has signed a licensing deal potentially worth more than 10 million US dollars although it's held back lifting its profit forecast. Audio
AFT Pharmaceuticals slims losses, sets for growth
The drug maker, AFT Pharmaceuticals, has slimmed its losses after cutting its research and development spend, and selling more of its pain relief products overseas. Audio
AFT still in the red but reduces loss
AFT Pharmaceuticals has reduced its net loss by a third to 10-point-1 million dollars after seeing strong growth in its offshore operations. Audio
AFT loss narrows in half-year
The maker of the Maxigesic painkiller has narrowed its half-year loss because of higher sales in Australia. Audio
AFT makes bigger loss but expects a return to profitability
The listed drug maker, AFT Pharmaceuticals, has reported a bigger full year loss, but expects to return to profitability within the next couple of years. Audio
Business briefs
The listed drug manufacturer, AFT Pharmaceuticals, says its sinus treatment device, NasoSURF, has been registered in the United States, which is a first step to full commercialisation of the product. Audio
AFT H1 loss in line with expectations
The drug maker, AFT Pharmaceuticals, has reported an increased first half loss, in line with expectations, as it spent more on marketing and research and development. Audio
AFT hitches wagon to Maxigesic
Recently-listed drug maker AFT Pharmaceuticals is banking on its main product, the painkiller Maxigesic, to drive the company's fortunes over the coming year. Audio
AFT Pharmaceuticals to licence Maxigesic in 69 more countries
The Auckland-based drugmaker, AFT Pharmaceuticals, is partnering with a Swiss-based pharmaceutical company to licence its painkiller, Maxigesic, for sale in a further 69 countries. Audio
Drug company AFT to float on stock exchange
Auckland-based drugmaker AFT Pharmaceuticals says its planned listing on the New Zealand and Australian stock exchanges is more likely to ensure it remains a local company and keep it out of the hands… Audio
Drug company to float on stock exchange
Auckland-based drugmaker AFT Pharmaceuticals is planning a $33.2 million share float to fund future product research and market growth.
Drug company AFT to float on stock exchange
Auckland-based drugmaker AFT Pharmaceuticals is planning a 33-million share float and wants to list on the New Zealand and Australian stock exchanges by Christmas. Audio